Selexipag is a selective prostacyclin receptor agonist used to treat pulmonary arterial hypertension. It improves exercise capacity and reduces hospitalization risk. Its clinical relevance lies in managing high blood pressure in the lungs. In summary, Selexipag is vital for treating pulmonary hypertension.
Selexipag activates IP receptors, leading to vasodilation and reduced pulmonary artery pressure.